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Since immune responses play a major role in the 
development or connective tissue diseases, it is not 
surprising that a number of laboratory studies reflect 
these responses. Prior to the 1940s when rheumatoid 
and LE factors became widely known, one relied 
mainly on erythrocyte sedimentation rate and serum 
electrophoresis to identify protein abnormality. Ele­
vated sedimentation rate depends on rouleaux forma­
tion, and rouleaux formation is dependent upon large 
asymmetric molecules of fibrinogen and gamma 
globulin in plasma. The demonstration of gamma 
globulin has become the cornerstone of the immuno­
logist's edifice. It is amazing to see how the sub­
specialty or immunology has mushroomed to involve 
the many facets of disease processes such as con­
nective tissue diseases, skin diseases, gastrointestinal 
diseases, renal diseases, and cancer. More recently, 
immune deficiency diseases have included the pe­
diatrician in the ever-enlarging field of immunology 
as has the modern-day discovery of human leukocyte 
antigen (H L-A) testing and tissue typing included the 
geneticist. 
In this paper, I will discuss four connective tissue 
diseases-rheumatoid arthritis, ankylosing spondy­
litis, systemic lupus erythematosus, and mixed con­
nective tissue disease syndrome-and the role immu­
nological processes play in their pathogenesis. I will 
also comment upon certain laboratory tests that use 
immunological methods in making a diagnosis. 
• This is publication No. 110 f"rorn the Charles W. Thomas 
Arthritis Fund. Medical College or Virginia. 
Correspondence and reprint requests to Dr. Robert Irby, Di­
vision of Immunology and Connective Tissue Diseases, Box 788. 
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I. Rheumatoid Arthritis. 
It is believed that an immune process plays a role 
in the perpetuation of rheumatoid arthritis and there 
are at least five items which may provide evidence for 
this hypothesis. 
I. Lymphoid cell infiltration of the synovial 
membrane with follicle formation. Note sim­
ilarity to architecture of lymph node (Figs IA 
and IB). 
2. Local synthesis of IgG and rheumatoid factor 
by plasma cells in the synovium as demon­
strated by Smiley et al.' 
3. Decreased synovial fluid complement in some 
cases. and in other cases decreased serum 
complement as demonstrated by Ruddy and 
Schur.'·3 
4. Presence of lgG and IgM and complement 
components in the synovial lining cells and in 
remote sites of tissue damage indicating that 
some immunological process is taking place 
also at distant sites.' 
5. Presence of rheumatoid factor components 
and complement in leukocytes of synovial 
fluid cells.' 
The current concept is that IgG is produced in 
rheumatoid synovial membrane by an unknown stim­
ulus: this in turn stimulates production of lgM by 
plasma cells of the synovium and lymph nodes. Why 
IgG. which is a product of the human system, should 
serve as an antigen for IgM antibody production. is 
unknown: however. immune events may depend 
upon circulating complexes which may or may not be 
important in pathogenesis. There are some who feel 
that rheumatoid factor plays a protective role similar 
to the antistreptolysin titer in streptococcal infection, 
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Fig IA-Microscopic view (medium power) of synovial mem­
brane showing "nesting" of lymphocytes in perivascular area of 
synovium. 
while others feel that in certain systems it plays a part 
in the inflammatory mechanism. The basic pathology 
in these diseases seems to be vasculitis; hence the term 
collagen-vascular disease arose, which is a misnomer, 
since collagen is not the only connective tissue in­
volved. In rheumatoid arthritis with high rheumatoid 
factor titers and many subcutaneous nodules, one is 
more likely to see those with severe disease: pe­
ripheral neuritis, vasculitis, and leg and fingertip ulce­
rations. In these patients one may find evidence of 
antigen-antibody complement complex deposition in 
the vessels leading to the ulcers and in the perineural 
vessels of the peripheral nerves (Figs 2A, 28 and Figs 
3A, 38). 
There are a number of immunological tests 
available to make a diagnosis of rheumatoid arthritis. 
The three currently in use at the Medical College of 
Virginia are the slide latex test, sensitized human cell 
test (SHC), and the sensitized sheep cell test (SSC). 
The latex test is the most sensitive and the sheep cell 
test is the most specific for the presence of rheuma­
toid factor. Sometimes there are false-positive latex 
tests in older patients and in patients with large 
amounts of gamma globulin present. The SSC may 
be positive in low titers and in other connective tissue 
diseases. In general, all three tests employ the same 
principle. The particle, whether it be latex, human red 
cells, or sheep cells, is coated with lgG from one 
source or another, which will agglutinate in the pres­
ence of rheumatoid factor. If the sheep cell test is 
positive in a significant titer, the chances are over 90% 
that the patient has rheumatoid arthritis. It should be 
remembered that a large number of patients do not 
show rheumatoid factor, and these patients are classi­
fied as seronegative rheumatoid arthritis patients (Fig 
4 and Fig 5). 
We can identify rheumatoid factor in serum, 
demonstrate that it is produced by plasma cells in the 
synovium, and can state that in certain cases of rheu­
matoid arthritis it plays a pathogenetic role. 
Fig JB-View (lower power) showing follicle formation within 
the synovium. Note similarity lo microscopic picture of lymph 
node. This is thought to be the site of rheumatoid factor syn­
thesis. 
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Fig 2A-lndolent leg ulcer in a 64-year-old male with rheuma­
toid arthritis which ultimately required below-the-knee amputa­
tion. 
II. Ankylosing Spondylitis. 
We generally categorize this as a separate disease 
entity from rheumatoid arthritis, although it has 
many similarities to that disease. There are, however, 
five specific differences: 
I. Sex and age of onset-more common in 
young males. 
2. Spine and girdle joints involved as opposed to 
peripheral joints, although peripheral joints 
may be involved in ankylosing spondylitis. 
3. Pathology is that of ankylosis, rather than 
bone destruction as seen in peripheral arthri­
tis. 
4. Absence of rheumatoid factor. 
5. Presence of a high incidence of H L-A B-27 
antigen. 
Fig 28-Area or vasculitis (medium power) in the center of a 
nerve trunk or the lower extremity. Note perivascular changes 
in the nutrient artery of the trunk. 
Fig )A-Digital vasculitis in a patient with rheumatoid ar­
thritis with gangrenous changes. 
HL-A stands for Human Leukocyte Antigen, 
and B-27 refers to its genetic locus on the chromo­
some. All of this is an outgrowth of tissue typing 
necessary in renal transplantation. We have known 
for some time that ankylosing spondylitis patients 
have a tendency to familial clustering, and there has 
been a low incidence of spondylitis in American and 
African blacks. In 1949, Toone reported studies from 
the McGuire Veteran's Hospital indicating the pau­
city of blacks who suffered from ankylosing spondy­
litis.6 Baum later confirmed this in a larger group of 
patients from a Veteran's cooperative study (Table 
I).' Schlosstein et al, and Brewerton et al, had found 
that there was a high correlation between the pres­
ence of H L-A B-27 antigen in ankylosing spondy­
litis-as high as 88% to 96%-and normal (8% in a 
controlled Caucasian population) (Table 2 ).8· 9 There 
Fig 38-Vasculitis and perivasculitis (medium power) of the 
nccrot121ng vanety showmg obhterat1on <ii the artery of the 
foot. 
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lgG 75 Antigen 
(Products of Self) 
Rheumatoid Factor Formation 
lgM 195 
Auto-Antibody 
22 S 
RF Complex 
Fig 4-Rheumatoid factor formation. Rheumatoid factors are 
antibodies which react with other immunoglobulins to form a 
rheumatoid factor complex in serum. 7S refers to sedimentation 
constant in the ultracentrifugation analysis (Svedberg units). 
are other diseases which have 8-27 as a genetic 
marker. These include Reiter's syndrome, acute ante­
rior uveitis, psoriasis with spondylitis, and others. 
To better understand the immunological pro­
cesses in developing a test such as the lymphocyte 
microcytotoxicity test (LMCT), it is important to 
understand the mechanics of the HL-A testing pro­
cedure. The LMCT is performed approximately as 
demonstrated in Figure 6. 
I. Specific HL-A 8-27 antiserum from multi­
parous women, or from those who have un­
dergone numerous transfusions as a source of 
developing 8-27 antibodies, is used. 
2. The patient's lymphocytes to be tested for 8-
27 antigen are prepared and mixed with the 
antisera and rabbit complement in the cham­
ber wells. 
Test For Rheumatoid Factor 
Negative Positive 
Fig 5-Test "ror rheumatoid factor. Rheumatoid factor complex 
will a$glutinate either latex particles, human RBC or sheep RBC 
when sensitized with IgG. In the square at lower right the 
well of.the left shows a negative test and on the right a positive 
test wioft latex irarticles. 
3. The addition of trypan blue dye will stain the 
interior of lymphocytes which have been 
lysed by the antigen-antibody complement re­
action. These lymphocytes are then counted 
under inverted phase microscopy to deter­
mine if the number of lysed cells is sufficient 
to make a specific identification of 8-27 an­
tigen. 
One may conclude then that the HL-A 8-27 
antigen is a genetic marker for the development of 
certain diseases in which spondylitis seems to be a 
common denominator. However, the part this 
marker plays in the pathogenesis of the disease is 
unknown. 
Ill. Systemic Lupus Erythematosus (SLE). 
There is no other connective tissue disease which 
has evoked more interest among immunologists than 
lupus; it might be labeled "the immunologist's de­
light." The ability to diagnose this disease stemmed 
from the Hargraves' LE cell test in 1948 through 
various patterns of antinuclear antibody (ANA) test­
ing, through the LE band test, and through the 
"lumpy-bumpy" deposits in the glomeruli. 
If one understands the basic concept of produc­
tion of experimental serum sickness, which was so 
well demonstrated by Dr. Frank Dixon with the for­
mation of immune complexes, one might understand 
more clearly the pathogenesis of such diseases as 
glomerulonephritis, rheumatic fever, SLE, and per­
haps even rheumatoid arthritis (Fig 7 ). '0 The parallel 
between these findings in experimental serum sick­
ness and human SLE and the occurrence of a wide 
range of autoantibodies against nuclear and tissue 
antigens, provides strong support for an immunolo­
gical process in SLE. These antibodies include anti­
DNA antibodies, anti-DNA histone antibodies, anti­
ribonucleoprotein (RNP) antibodies, anti-Smith 
(Sm) antibodies, and a host of others. The demon­
stration of DNA and anti-DNA antibodies in the 
TABLE I 
Racial Aspects of Ankylosing Spondylitis• 
I. Random study McGuire VA Hospital: 26 white. 3 black.­
Toone 1949 
2. Combined VA Hospital study, 301 patients: 10% black.-
Baum 1971 
3. HL-A 27 absent in Black Africans. 
4. HL-A 27 only 4% in Black Americans. 
5. HL-A 27 present in 8 of IO Black American spondylitics. 
*The above figures demonstrate the relationship of HL-A 
27 and ankylosing spondylitis on Black Americans. 
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TABLE 2 
HL-A 27 in Rheumatic Disease Patients• 
Condition Presence of H L-A 27 Percentage Source 
Normal 
Rheumatoid arthritis 
Gout 
Ankylosing spondylitis 
Reiter's syndrome 
Acute anterior uveitis 
Psoriasis 
Psoriasis/spon d yl iti s 
119/1456 
10/119 
6/66 
35/40 
72/75 
25/33 
26/50 
9/156 
6/44 
10/14 
8% Russell. 1972 
Brewerton. 197 3 
Schlosstein. 1973 
White. 1972 
8% Schlosstein. 1973 
9% Schlosstein. 1973 
88% Schlosstein. 1973 
96% Brewerton. 197 3 
76% Brewerton. 197 3 
52% Brewerton. 1973 
6% White, 1972 
14% Russell. 1972 
71% Metzger. 1974 
• A compilation of rheumatic diseases and H L-A 27 shows its strong association with ankylosing spondylitis. Reiter's 
syndrome. and psoriatic spondylitis. 
8-27 ASSAY 
#I #2 #3 
Undiluted 0 0 0 B-27 ontisero 
Diluted 0 0 0 B-27 ontisero 
+ 
Lymphocytes to be tested 
+ 
Trypon Blue 
( Positive test) ( Negative test) 
Fig 6-Lymphocyte microcytotoxicity test for B-27 antigen. 
Lymphocytes to be tested for B-27 antigen are added to each 
of three donor wells of diluted and undiluted specific B-27 anti­
sera. With addition of complement and t rypan blue dye, cells 
will lyse and stain positively with blue dye if B-27 antigen is 
present. 
human kidney in SLE reinforces the concept that 
SLE i, an example of an immune-complex deposition 
disease involving autoantibodies.11•12 
Prior to the widespread use of antinuclear an­
tibody testing for the diagnosis of SLE, one relied 
primarily on the demonstration of hematoxylin bod­
ies in fixed tissue, or the presence of LE cells in the 
serum. Hematoxylin bodies are globular masses of 
nuclear material which stain blue with hematoxylin 
and eosin (H & E) stain and are histochemically 
identical with the inclusion body of an LE cell. Severe 
vasculitis is the hallmark of SLE, and fibrinoid de­
posits in vessels have been shown to be composed 
chiefly of DNA, anti-DNA, and complement com­
ponents. The use of various immunological tests to 
determine the presence of ANA have taken the place 
of the LE cell test in making the diagnosis of SLE. 
The method used here is the indirect immunofluores­
cent antibody test, which employs mouse liver cells as 
the source of nuclear antigen. If antinuclear anti­
bodies are present, various patterns of immunofluo­
rescence will appear, depending on what type of an­
tinuclear antibody is present in the patient's serum. 
The patient's serum to be tested is added to the 
mouse liver cells and will adhere to the nuclear an­
tigen even when washed. When anti-human gamma 
globulin, which is commercially prepared and stained 
with fluorescin is added, a bright apple-green fluores­
cence will appear in the preparation when viewed 
under ultraviolet light (Fig 8). We have come to 
recognize four different fluorescent staining patterns, 
which may help in differentiating different patterns of 
disease expression in lupus. These include the homo­
geneous or diffuse pattern, indicating antibodies to 
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Fig 7-Circulating BSA-anti-BSA complexes: development of 
lesions. Correlation between formation of immune complexes 
with bovine serum albumin and appearance of lesions of heart. 
joints. and kidneys of rabbits with experimental serum sickness 
induced by injection of tagged BSA. 
single- or double-stranded DNA: the peripheral or 
ring pattern, usually indicating the presence of anti­
bodies to double-stranded DNA with active lupus 
present, usually with renal involvement: the nucleolar 
pattern, in which the nucleoli of the mouse liver cells 
take the stain, can be found in patients with systemic 
sclerosis or Sjogren's syndrome; and the speckled 
pattern, which stains for ribonucleoprotein and has a 
fibrillar appearance in the nucleus and is found in 
mixed connective tissue disease syndrome. It should 
be emphasized that these staining patterns and the 
statements regarding them are generalizations and 
should not be interpreted as explicit evidence in these 
cases. Sometimes we see a mixture of patterns, which 
may confuse the issue (Fig 9). 
In some cases of SLE, where a drug such as 
hydralazine or procainamide is suspected in produc­
ing the LE phenomenon and antinuclear antibodies, 
a hemagglutination test or agar gel precipitation test 
using single- or double-stranded DNA may be used. 
Antibodies to single-stranded DNA are usually pres­
ent in drug-induced SLE, whereas antibodies to 
double-stranded DNA may indicate active lupus with 
renal involvement. The A NA test is superior to the 
LE cell test in making a diagnosis in SLE because 
only 75% to 90% of patients with active SLE will have 
positive LE cell tests. Almost all patients with lupus 
will have a positive ANA test. 
The conclusion here is that SLE is the immunol-
ogist's disease-many types of autoantibodies are 
present, which can be demonstrated by various im­
munodiffusion and immunofluorescent techniques. 
These autoantibodies are thought to play a specific 
role in the pathogenesis of SLE, particularly where 
there is renal involvement. 
IV. Mixed Connective Tissue Disease (MCTD). 
The introduction of the term speckled pattern of 
A NA immunofluorescence and the presence of ri­
bonucleoprotein and Smith antigens opens the door 
to mixed connective tissue disease syndrome. 
The clinical picture of MCTD reveals it as a 
syndrome consisting of many of the features of the 
connective tissue disorders including rheumatoid ar­
thritis with arthritis and arthralgias and rheumatoid 
factor. SLE with skin rashes and speckled pattern of 
antinuclear antibody immunofluorescence, progres­
sive systemic sclerosis with Raynaud's phenomenon 
and thickening of the skin. and polymyositis with 
A 
Patient's 
Serum 
8 
Fluoresce in 
Anti yG 
Fig 8-lndirecl immunoOuorescent staining for antinuclear anti­
bodies. Mouse liver cells are used as the substrate for source of 
nuclear antigen. The r,atien1s· serum (A) containing antinuclear 
antibodies binds to the nuclei leaving a coating. After washing. 
the preparation is incubated with an anti-human gamma globulin 
(8) which hinds only al the site where antinuclear antibody is 
bound. Nuclei exposed to SLE serum will fluoresce when ex­
amined under the Ouorescence microscope. 
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NUCLEAR PATTERNS OF ANA 
ANTIGEN STAINING PATTERN 
CLINICAL CORRELATION 
Histone Component 
Deoxyribonucleoprotein 
DNA 
RNA 
R ibonucleoprotein 
RNP 
Homogenous 
or 
Diffuse 
Peripheral 
or 
Ring 
Nucleolar 
Speckled 
SLE 
RA 
OTHERS 
Active Lupus usually 
with nephritis 
SCLERODERMA 
SJOGREN'S 
SLE 
MCTD 
Fig 9- Different patterns of ANA testing. Antigen, pattern of fluorescent staining, and clinical correlation in the four types of nuclear 
antibody tests. 
myopathy and muscle enzyme changes. In other 
words, it is a "mishmash" of the connective tissue 
diseases, but generally patients are thought to have a 
better prognosis with this syndrome and as a rule do 
not have severe renal or central nervous system 
(CNS) involvement as those with systemic lupus. 
Concerning the diagnosis of MCTD, Gordon 
Sharp at the University of Missouri, who has done 
much work in this disease, feels that a diagnosis can 
be made if the clinical picture fits and one can demon­
strate antibodies to extractable nuclear antigen 
(ENA) which are RNAse sensitive. 13 Extractable nu­
clear antigen is prepared from calf thymus cells con­
taining mainly RNP and Sm antigens. This test is 
performed either by an immunodiffusion technique 
or by hemagglutination method, to demonstrate anti-
bodies to RNP and Sm antigens. RNP can then be 
removed from either test system by the addition of 
RN Ase, leaving only Sm antigen if it is present. If a 
precipitin band remains in the immunodiffusion dish 
after RNAse is added, this is Sm antigen antibody 
band, which may be present in SLE and may indicate 
a poorer prognosis than in those patients with 
MCTD (Fig 10). The hemagglutination test for RNP 
and Sm antigen is very similar to the technique em­
ployed in the tanned sheep cell test in rheumatoid 
factor. ENA is added to tanned sheep cells to coal the 
cells with RNP and Sm antigens. When the patient's 
serum containing antibodies to ENA is added, agglu­
tination results, indicating a positive test. If after 
RNAse is added there is no agglutination and the 
sheep cells fall lo the bottom of the tube, this in-
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ENA Test 
8 8 RN As� 
§ 8 
Before RNAse After RNAse 
Fig 10-Extractable nuclear antigen test (ENA): Precipitating Antibodies to RNP and Sm Antigens. ENA (RNP and Sm antigens) 
in center well of agar gel before RNAse show precipitin bands with both MCTD and SLE sera. After RNAse is added lo center well 
in figure on right bands for MCTD, sera are no longer present, leaving only Sm precipitin bands for SLE sera. 
HEMAGGLUTINATION TEST 
FOR RNP AND Sm ANTIGENS 
Fig 11-Hemagglutination test for RN P and Sm Antigens. Row I 
represents a positive ENA agglutination in a titer over 100,000 
for MCTD: Row 2 demonstrates the effect after RNAse has 
been added, identifying an RNAse-sensitive antibody, and the 
red cells fall to the bottom of the well, concluding that this 
serum contains RNP antibodies found in MCTD: Rows 3 and 
4 are sera from a normal individual with negative ENA tests 
before and after RNAse: Rows 5 and 6 represent SLE sera 
which contain antibodies to ENA which are RNAse-resistant, 
indicating no RNP to be present and Sm antigen accuunling 
for the persistent agglutination. Control sera are in the column 
on the right. 
dicates that only RNP antibodies for MCTD are 
present. If on the other hand the agglutination re­
mains after RNAse is added, this would indicate 
other antibodies, such as those to Sm antigen, are 
present, as is seen in SLE. Titers over I: I 0,000 are 
thought to be significant in the interpretation of this 
test (Fig 11 ). 
For a diagnosis of mixed connective tissue dis­
ease, high titers of hemagglutination antibodies to 
ENA and no antibodies to ENA after RNAse is 
added are required. A speckled pattern on fluorescent 
A NA test is another indication for the diagnosis. 
In a group of 100 patients studied by Sharp et al, 
74% had RN Ase-sensitive ENA by hemagglutination 
or immunodiffusion techniques, and had mixed con­
nective tissue disease. 13 Of the 26% who were RN Ase­
resistant ENA patients, a large majority had SLE. 
This group then was composed of those patients in 
whom the immunodiffusion and hemagglutination 
tests showed the presence of antibodies to Sm an­
tigen. 
One can conclude, therefore, that those patients 
who demonstrated antibodies to ENA, which are 
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R Ase-sensitive (RNP antibody), may have MCTD 
and are less likely to have renal and CNS in­
volvement and have a better prognosis. 
Summary. 
I. Rheumatoid factor can be identified in the 
sera of certain patients with rheumatoid ar­
thritis, is produced in synovial cells. and may 
have a role in pathogenesis in so111e patients. 
2. H L-A B-27 antigen is a genetic marker for 
development of certain diseases in which 
spondylitis is a common denominator: its role 
in pathogenesis is unknown. 
3. Systemic lupus erythematosus is an example 
of antigen-antibody complement complex 
deposi.tion disease. DifTerenl types of antinu­
clear-antibody tests are associated with differ­
ent patterns of disease expression. 
4. Patients with antibody lo the ribonucleopro­
lein component of extractable nuclear antigen 
may have mixed connective tissue disease and 
are less likely lo have severe renal and CNS 
involvement. 
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